Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00505583

Enrollment

Registered

2007-07-23

Start date

2007-07-31

Completion date

2007-12-31

Last updated

2019-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methadone-maintenance Subjects

Brief summary

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

Interventions

DRUGMOA-728

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

Inclusion: 1. Healthy men or women, aged 18 to 65 years. 2. History of methadone treatment for at least 1 month, at a dose \>=30 and \<=140 mg/day. Exclusion: 1. History or active presence of clinically important medical disease. 2. Allergy to opioids.

Design outcomes

Primary

Measure	Time frame
To characterize the pharmacodynamics of single oral doses of MOA-728 compared to a positive control of MOA-728 administered intravenously in subjects on stable methadone maintenance.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026